April 19 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* ENTERED WORLDWIDE EXCLUSIVE LICENSING AGREEMENT AND MASTER SERVICES AGREEMENT WITH EVOTEC SE
* WILL PAY AN IMMEDIATE UPFRONT OF A$1.6 MILLION
* AGREEMENT FOR LICENSE OF GLOBAL RIGHTS TO EVT801
* EXPECTS TO LAUNCH A PHASE I CLINICAL TRIAL IN CY2021